We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
6 own
18 watching
Current Price
$8.16
$-0.61
(-6.96%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
1,186.12M
52-Week High
20.69
52-Week Low
3.48
Average Volume
3.7M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,186.12M
52-Week High20.69
52-Week Low3.48
Average Volume3.7M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program in the field of hematological malignancies; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. is headquartered in New York, New York.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Zolmax
2 months ago
TG Therapeutics, Inc. (NASDAQ:TGTX Get Rating) gapped up before the market opened on Wednesday . The stock had previously closed at $6.00, but opened at $6.26. TG Therapeutics shares last traded at $6.33, with a volume of 24,481 shares trading hands. Wall Street Analyst Weigh In Several research ...
PR Newswire
2 months ago
TGTX DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages TG Therapeutics, Inc. Investors to Secure Counsel Before Important Friday Deadline in Securities Class Action - TGTX TGTX DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages TG Therapeutics, Inc. Investors to Secure Counsel Before...
PR Newswire
2 months ago
FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in TG Therapeutics, Inc. with Losses of $100,000 to Contact the Firm FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in TG Therapeutics, Inc. with Losses of $100,000 to Contact the Firm PR Newswire LOS ANGELES, Sept. 16...
Business Wire
2 months ago
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against TG Therapeutics, Inc. (TG Therapeutics or the Company) (NASDAQ: TGTX) and certain of its officers, on behalf of a class consisting of all persons and entities other...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$8.16
$-0.61
(-6.96%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00